<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820364</url>
  </required_header>
  <id_info>
    <org_study_id>CLGX818X2102</org_study_id>
    <secondary_id>2012-004798-17</secondary_id>
    <nct_id>NCT01820364</nct_id>
  </id_info>
  <brief_title>LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma</brief_title>
  <acronym>LOGIC</acronym>
  <official_title>Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity
      of LGX818 in combination with selected agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II two part multi-center, open-label study. Part I: LGX818 single agent
      treatment until progression Part II: Combination treatments of LGX818 + MEK162, or BKM120,
      or BGJ398, or INC280, or LEE01 to assess the clinical efficacy, to further evaluate the
      safety of the drug combinations in patients with locally advanced or metastatic BRAF mutant
      melanoma after relapse on LGX818, and to determine the maximum tolerated dose of the
      combinations (when not established previously). These drug combinations are selected and
      assigned to patients based on documentation of molecular resistance mechanism.

      Patients with BRAF mutant melanoma treated by LGX818 single agent in other studies can be
      enrolled directly in Part II of CLGX818X2102 after relapse.

      Dose-escalations in the combination arms for which no MTD has been established will be based
      on the recommendations of a Bayesian logistic regression model guided by an escalation with
      overdose control criterion
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Dose Limiting Toxicities (DLTs) in Cycle 1 of Combination Part (Part II)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration and derived PK parameters of LGX818 and combination partners</measure>
    <time_frame>3years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) (Part I)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)(Part I and II)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) (Part II)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Part II)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular status (mutation/amplification/expression) of markers relevant to the RAF/MEK/ERK and PI3K/AKT pathways</measure>
    <time_frame>baseline, at progression with LGX818 single agent treatment up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rational combination of LGX818 + MEK162</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rational combination of LGX818 + LEE011</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + BGJ398</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rational combination of LGX818 + BGJ398</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + BKM120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rational combination of LGX818 + BKM120</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 + INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rational combination of LGX818 + INC280</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGX818</intervention_name>
    <description>BRAF inhibitor</description>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
    <arm_group_label>LGX818 + LEE011</arm_group_label>
    <arm_group_label>LGX818 + BGJ398</arm_group_label>
    <arm_group_label>LGX818 + BKM120</arm_group_label>
    <arm_group_label>LGX818 + INC280</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>MAPK1/2 inhibitor</description>
    <arm_group_label>LGX818 + MEK162</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>CDK4/6 inhibitor</description>
    <arm_group_label>LGX818 + LEE011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGJ398</intervention_name>
    <description>FGFR inhibitor</description>
    <arm_group_label>LGX818 + BGJ398</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <description>Pi3K inhibitor</description>
    <arm_group_label>LGX818 + BKM120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>c-Met inhibitor</description>
    <arm_group_label>LGX818 + INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally advanced or metastatic melanoma

          -  confirmed BRAF V600 mutation

          -  patients naïve to a selective BRAF inhibitor

          -  fresh tumor biopsy at baseline, and patient agrees for a mandatory biopsy at the time
             of relapse

          -  life expectancy ≥ 3 months

          -  World Health Organization (WHO) Performance Status ≤ 2.

        Exclusion Criteria:

          -  Previous treatment with RAF-inhibitor

          -  Symptomatic or untreated leptomeningeal disease

          -  Symptomatic brain metastases.

          -  Known acute or chronic pancreatitis

          -  Clinically significant cardiac disease

          -  AST/SGOT and ALT/SGPT &gt; 2.5 x ULN, or &gt; 5 x ULN if liver metastases are present

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral interventional drug

          -  Previous or concurrent malignancy.

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation

        Specific exclusion criteria for each treatment arm:

        LGX818/MEK162:

        History or current evidence of retinal disease History of Gilbert's syndrome.

        LGX818/BKM120:

        Patients with diabetes mellitus requiring insulin treatment Patient has mood disorders

        LGX818/BGJ398:

        History and/or current evidence of ectopic mineralization/ calcification Current evidence
        of corneal disorder/ keratopathy Patients with current evidence of endocrine alteration of
        calcium/phosphate homeostasis.

        History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade ≥ 3 and/or
        magnesium levels below the clinically relevant lower limits before study entry.

        Ionized (i) calcium (Ca) &gt; ULN Serum inorganic phosphorus (Pi) &gt; ULN

        LGX818/LEE011 History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade ≥ 3
        and/or magnesium levels below the clinically relevant lower limits before study entry.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona Mayo</name>
      <address>
        <city>*see Various Departments*</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles Onc Dept</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Onc Dept</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Dept Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Sanchez</last_name>
      <phone>646-888-4339</phone>
      <email>sanchea2@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Michael K. Postow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Onc Dept</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>CANN.askSarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey R. Infante</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center SC - Dept of Oncology .</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>US Oncology Central Monitoring</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 26, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open-label study;BRAF inhibitor;LGX818;MEK162;LEE011;BGJ398;BKM120;INC280;MAPK1/2 inhibitor; Pi3K inhibitor; FGFR; c-Met; CDK4/6; metastatic melanoma;BRAF; V600</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
